RESULTS IN PRIMARY PROGRESSIVE MS (PPMS)
RESULTS IN PRIMARY PROGRESSIVE MS (PPMS)
RESULTS IN PRIMARY PROGRESSIVE MS (PPMS)
Find out why OCREVUS may be the right choice for treating your primary progressive multiple sclerosis (PPMS). See results and understand how OCREVUS was evaluated in a clinical trial.
DISABILITY PROGRESSION
*OCREVUS was studied against a placebo. A placebo is a substance or treatment that has no active medicine. It is common for treatment to be compared with a placebo when there are no existing approved treatments to compare it with. Disability progression was measured using a tool called the Expanded Disability Status Scale (EDSS). Disability progression was confirmed 3 months after the initial neurological worsening.
†Disability progression was also confirmed after 6 months.
Disability progression is the increase in physical disability that happens over time for people with MS. How and when it happens is different for everyone. It can also vary in severity.
Some people may find they struggle with walking or remembering their “to-do” list. Others may experience tingling or numbness or blurred vision. While some may dismiss or overlook these symptoms, they may be a sign of disability progression—and over time, decreased mobility.
Disability progression is measured using a tool called the Expanded Disability Status Scale (EDSS). It assesses your functionality or changes to function in the areas listed below. OCREVUS was not proven to individually reduce each of these measured endpoints.
Infusion reactions are a common side effect of OCREVUS, which can be serious and may require you to be hospitalized. You will be monitored during your infusion and for at least 1 hour after each infusion of OCREVUS for signs and symptoms of an infusion reaction. Tell your healthcare professional or nurse if you get any reactions. Please visit Safety & Side Effects for more information.
BRAIN LESIONS
OCREVUS reduced the volume of T2 hyperintense lesions, while T2 lesion volume increased in people taking placebo.
The average change in volume of T2 lesions was -0.39 cm3 for OCREVUS compared with 0.79 cm3 for placebo.‡
‡OCREVUS was evaluated in a study including 732 people who were treated with OCREVUS or placebo for at least 120 weeks.
While you may not see them, MS can cause lesions to develop in the central nervous system (CNS). Over time, if these lesions progress, some of them may lead to a variety of symptoms that may be more noticeable. Reducing the development of new lesions is an important step in slowing MS progression.
OCREVUS ZUNOVO® Clinical Study
This study measured the amount of medicine in the bloodstream, which is commonly done to check that the injection works like infusion. The results of the study showed there were no clinically significant differences between OCREVUS ZUNOVO and OCREVUS.
After reviewing the results and safety, having an honest conversation with your doctor is the next step. Our Doctor Discussion Guide can help shape the conversation around your symptoms, lifestyle, and goals so that you might find a treatment that is right for you.
Click below to either create a personalized list of questions to ask at your appointment or view a guide with commonly asked questions.
Whether you’re getting OCREVUS ZUNOVO injections or OCREVUS infusions, both treatment options are just 2 times a year.§ Your treatment may be given at an infusion center, your doctor’s office, or at home depending on what you and your doctor decide is right for you. Find out more about what to expect at your treatment appointment.
§First treatment will be split into 2, for a total of 3 treatments the first year.
Stuifbergen A, Becker H, Phillips C, Horton S, Morrison J, Perez F. Experiences of African American Women with Multiple Sclerosis. Int J MS Care. 2021;23(2):59-65.
Stuifbergen A, Becker H, Phillips C, Horton S, Morrison J, Perez F. Experiences of African American Women with Multiple Sclerosis. Int J MS Care. 2021;23(2):59-65.
Langer-Gould AM, Gonzales EG, Smith JB, Li BH, Nelson LM. Racial and Ethnic Disparities in Multiple Sclerosis Prevalence. Neurology. 2022;98(18):e1818-e1827.
Langer-Gould AM, Gonzales EG, Smith JB, Li BH, Nelson LM. Racial and Ethnic Disparities in Multiple Sclerosis Prevalence. Neurology. 2022;98(18):e1818-e1827.
Okai AF, Howard AM, Williams MJ, et al. Advancing Care and Outcomes for African American Patients With Multiple Sclerosis. Neurology. 2022;98(24):1015-1020.
Okai AF, Howard AM, Williams MJ, et al. Advancing Care and Outcomes for African American Patients With Multiple Sclerosis. Neurology. 2022;98(24):1015-1020.
Amezcua L, McCauley JL. Race and ethnicity on MS presentation and disease course. Mult Scler. 2020;26(5):561-567.
Amezcua L, McCauley JL. Race and ethnicity on MS presentation and disease course. Mult Scler. 2020;26(5):561-567.
Ingram M, Leih R, Adkins A, Sonmez E, Yetman E. Health Disparities, Transportation Equity and Complete Streets: a Case Study of a Policy Development Process through the Lens of Critical Race Theory. J Urban Health. 2020;97(6):876-886.
Ingram M, Leih R, Adkins A, Sonmez E, Yetman E. Health Disparities, Transportation Equity and Complete Streets: a Case Study of a Policy Development Process through the Lens of Critical Race Theory. J Urban Health. 2020;97(6):876-886.
Sohn H. Racial and Ethnic Disparities in Health Insurance Coverage: Dynamics of Gaining and Losing Coverage over the Life-Course. Popul Res Policy Rev. 2017;36(2):181-201.
Sohn H. Racial and Ethnic Disparities in Health Insurance Coverage: Dynamics of Gaining and Losing Coverage over the Life-Course. Popul Res Policy Rev. 2017;36(2):181-201.
Taylor J. Racism, Inequality, and Health Care for African Americans. The Century Foundation. December 19, 2019. Accessed April 16, 2023. https://tcf.org/content/report/racism-inequality-health-care-african-americans.
Taylor J. Racism, Inequality, and Health Care for African Americans. The Century Foundation. December 19, 2019. Accessed April 16, 2023. https://tcf.org/content/report/racism-inequality-health-care-african-americans.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.
Su navegador está configurado en español. ¿Preferirías el sitio en español?